Anavex Lf SC (AVXL) Stock Price, Quote & News

Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and A...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 689 3939

Website: www.anavex.com

Address:

630 5th Avenue, 20th Floor, New York, United States

Plexrec Jun. 26 at 8:22 PM

$AVXL Nice (recovery) high close--$9.57----it's been awhile !! Buyers awakening---forward looking----good news coming our way !!!!!

0 · Reply

georgejjl Jun. 26 at 8:06 PM

$AVXL AVXL stock closed at $9.57 +0.16 +1.70% with 622,283 shares bought today!!! Good luck and GOD bless,

0 · Reply

papatrick Jun. 26 at 7:52 PM

$AVXL did you see $SNPX scam today? haha market is crazy another sava runing for longer time

0 · Reply

papatrick Jun. 26 at 7:50 PM

$AVXL only shorting or a leak for our potential competitor $INMB ??

0 · Reply

papatrick Jun. 26 at 7:48 PM

$AVXL yes, cost must stay high at least the first 5 years. It must pay for R&D and patents and pay for futur dev. Blarcamesine#2 must be developped and pushed through ph1,2,3 worldwide. The one with only the right enentiomer, so 10 times less adverse effect, allowing 10x the actual dosage

0 · Reply

badprecog Jun. 26 at 6:28 PM

$AVXL I just asked Gemini what Blarcamesine should be priced at and it said $20K. I personally think it should be $6K and given to everyone upon initial diagnosis, and currently suffering from AD. But I guess after approval we will see how missling plays it out. At $6K and giving it to everyone Gemini calculated that it would save the EU between $11-64B annually if this strategy was employed because less progressed AD patients are far less expensive for the Healthcare System. However Gemini would still price it at $20K which I thought was interesting.

1 · Reply

badprecog Jun. 26 at 6:24 PM

$AVXL I think the one thing shorts don't realize is that for most of us this is not our only investment, and upon approval, if we like what we are hearing some of us will go crazy with greed and go all in. ;)

0 · Reply

SCLXSUX Jun. 26 at 6:01 PM

$AVXL - I blocked and reported both.

1 · Reply

DueBill Jun. 26 at 5:44 PM

$AVXL George… I like you believe in the science.. But promoting an old video that we have all seen doesn’t do much for me. I’d like to see… hear… from others who have been in trials or even know people who have benefited from Blarcamesine. This is the one and only reason for the small amount of skepticism in my gut. IF there were more success stories… REAL VERIFIED success stories… I’d absolutely double down on my abundance of shares. TODAY!

2 · Reply

Georgejj Jun. 26 at 5:32 PM

$AVXL The attached video illustrates just how effective Anavex’s blarcamesine really is: https://m.youtube.com/watch?v=8orzf4UXNLA Good luck and GOD bless,

0 · Reply

Does Anavex's Alzheimer's Drug Actually Confer Benefit?

May 15, 2025, 12:21 PM EDT - 6 weeks ago

The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)

May 14, 2025, 7:30 AM EDT - 6 weeks ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 13, 2025, 9:25 AM EDT - 6 weeks ago

Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 6 weeks ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 7 weeks ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 1, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Apr 30, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Apr 23, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Apr 21, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Apr 5, 2025, 11:30 AM EDT - 2 months ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Mar 31, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 24, 2025, 7:30 AM EST - 4 months ago

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Feb 14, 2025, 6:02 PM EST - 4 months ago

Anavex: Looking At Different Statistical Approaches Before EMA Opinion

Feb 12, 2025, 3:13 PM EST - 4 months ago

Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025

Feb 12, 2025, 9:59 AM EST - 4 months ago

Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript

Feb 12, 2025, 7:30 AM EST - 4 months ago

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Feb 5, 2025, 7:30 AM EST - 5 months ago

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Jan 27, 2025, 7:30 AM EST - 5 months ago

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Jan 15, 2025, 7:30 AM EST - 5 months ago

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

Jan 13, 2025, 7:30 AM EST - 5 months ago

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients

Jan 12, 2025, 11:21 AM EST - 5 months ago

Playing The Odds Of Anavex Alzheimer's Drug Approval

Jan 6, 2025, 7:30 AM EST - 6 months ago

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 27, 2024, 7:30 AM EST - 6 months ago

Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision

Dec 26, 2024, 10:31 AM EST - 6 months ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA PYPD

Dec 24, 2024, 8:50 AM EST - 6 months ago

Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis

Dec 23, 2024, 10:23 AM EST - 6 months ago

Anavex Life Sciences Corp. (AVXL) Q4 2024 Earnings Call Transcript

Dec 23, 2024, 7:30 AM EST - 6 months ago

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Dec 23, 2024, 7:00 AM EST - 6 months ago

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease

Dec 16, 2024, 7:30 AM EST - 6 months ago

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

Dec 9, 2024, 7:30 AM EST - 7 months ago

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 7 months ago

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

Nov 26, 2024, 7:30 AM EST - 7 months ago

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA

Nov 25, 2024, 7:30 AM EST - 7 months ago

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

Nov 6, 2024, 5:10 AM EST - 8 months ago

Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario

Oct 31, 2024, 4:00 AM EDT - 8 months ago

Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024

Oct 17, 2024, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Sep 3, 2024, 7:30 AM EDT - 10 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 12:19 PM EDT - 11 months ago

Anavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 11 months ago

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 11 months ago

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

Jul 30, 2024, 7:30 AM EDT - 11 months ago

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

Jul 28, 2024, 5:00 PM EDT - 11 months ago

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

Jun 20, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 22, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Expansion of Leadership Team

May 14, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

May 13, 2024, 1:45 PM EDT - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $500,000 to Contact the Firm

Plexrec Jun. 26 at 8:22 PM

$AVXL Nice (recovery) high close--$9.57----it's been awhile !! Buyers awakening---forward looking----good news coming our way !!!!!

0 · Reply

georgejjl Jun. 26 at 8:06 PM

$AVXL AVXL stock closed at $9.57 +0.16 +1.70% with 622,283 shares bought today!!! Good luck and GOD bless,

0 · Reply

papatrick Jun. 26 at 7:52 PM

$AVXL did you see $SNPX scam today? haha market is crazy another sava runing for longer time

0 · Reply

papatrick Jun. 26 at 7:50 PM

$AVXL only shorting or a leak for our potential competitor $INMB ??

0 · Reply

papatrick Jun. 26 at 7:48 PM

0 · Reply

badprecog Jun. 26 at 6:28 PM

1 · Reply

badprecog Jun. 26 at 6:24 PM

0 · Reply

SCLXSUX Jun. 26 at 6:01 PM

$AVXL - I blocked and reported both.

1 · Reply

DueBill Jun. 26 at 5:44 PM

2 · Reply

Georgejj Jun. 26 at 5:32 PM

$AVXL The attached video illustrates just how effective Anavex’s blarcamesine really is: https://m.youtube.com/watch?v=8orzf4UXNLA Good luck and GOD bless,

0 · Reply

45bulls Jun. 26 at 5:20 PM

$AVXL @MayoMobile - FYI a couple of new accounts are ripping you off and trying to build up a following. @mayo_mobile and @MayoMobile_ both followed my account today. @Stocktwits needs to ban these spam accounts

4 · Reply

papatrick Jun. 26 at 5:00 PM

$AVXL $ALT what does pple expect?? Results of $ALT drug are impressive, and the stock cut in half....bizarre... Strange world we are living in.

1 · Reply

old_salt Jun. 26 at 4:37 PM

$AVXL

0 · Reply

itsthrillhouse Jun. 26 at 4:33 PM

$AVXL Watch out for @MayoMobile impersonation and messages. Just got followed by a "Mayo_Mobile" who has stolen Mr. S's picture. Just a heads up. 👍🫡

6 · Reply

Malf77 Jun. 26 at 4:23 PM

$AVXL

0 · Reply

robseip Jun. 26 at 3:47 PM

$AVXL gettin close a million dollars traded!!!

0 · Reply

Ueberschlaefer Jun. 26 at 3:44 PM

$AVXL $ALT is a good look into pumptard psychology, what happens when a biotech crashes in price on weak data after intense, fanatical hyping. the coping, the hoping... it's all delicious. ALT pumptards are pretty fierce, but lack the true cultish devotion of AVXL. please god get me close to b/e...

1 · Reply

MisslingsBeautifulHair Jun. 26 at 3:39 PM

$AVXL 10.375% on fidelity now. This is getting silly

0 · Reply

Rudedog_1963 Jun. 26 at 2:29 PM

$AVXL $$$ANAVEX$$$

0 · Reply

badprecog Jun. 26 at 2:19 PM

$AVXL Just remember May 9th -2024 Earnings call Missling Stated: "To give you a sense of the level of interest, we noted before that the reason we submitted to the EMA was not because we thought it would be a good idea, but because we shared the majority of the data with the EMA beforehand, and asked for their input and their feedback, and their response was unambiguous to request to immediately file a submission." Pre - Peer reviewed journal, pre Extension data...

2 · Reply

old_salt Jun. 26 at 2:15 PM

$AVXL

0 · Reply

Gabriel_DS Jun. 26 at 2:01 PM

$AVXL holding the $9 wouldn't be that bad either

0 · Reply

Market Cap	816.16M
Revenue (ttm)	0.00
Net Income (ttm)	-43.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	622,285
Avg Vol	817,970
Day's Range	N/A - N/A
Shares Out	85.37M
Stochastic %K	79%
Beta	0.68
Analysts	Strong Sell
Price Target	$44.00